The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030
Roots Analysis is pleased to announcethe publication of its recent study, titled “Subcutaneous Biologics,Technologies and Drug Delivery Systems (3rdEdition), 2020-2030” report to its list of offerings.
Thereport provides a detailed study on the current market landscape and futurepotential of biologics designed for subcutaneous administration. In addition,the study provides an in-depth analysis of the formulation technologies anddrug delivery systems (focusing on large volume wearable injectors,autoinjectors, pen injectors, needle-free injectors, drug reconstitutionsystems, prefilled syringes and implants) that enable subcutaneous delivery ofthe biologic drugs. Amongst other elements, the report features the following:
§ Adetailed assessment of the current market landscape of commercially availableand clinical-stage biologics that are designed for delivery via thesubcutaneous route
§ Acase study on leading subcutaneous biologics (in terms of revenues generated),featuring details on mechanism of action, development history, annual sales,technology platform (if available), and a comparison of their intravenous andsubcutaneous formulations (if applicable).
§ Anassessment of the various subcutaneous formulation technologies along withinformation on developers, type of pharmacological molecule, route ofadministration, mechanisms of action and primary advantage(s).
§ Aninsightful three-dimensional comparison of the subcutaneous formulationtechnology developers, based on pipeline strength, supplier power of thedeveloper and primary advantages offered by their respective technologies.
§ Elaborateprofiles of key technology developers, featuring a brief overview of thecompany, its technology portfolio, product portfolio, financial information (ifavailable), recent developments and an informed future outlook.
§ Ananalysis of collaborations andpartnership agreements inked by the subcutaneous formulation technologydevelopers since 2011
§ Anin-depth review of the most advanced and popular subcutaneous drug deliverysystems, including large volume wearable injectors, autoinjectors, peninjectors, needle-free injectors, drug reconstitution systems, prefilledsyringes and implants
§ Acomprehensive product competitiveness analysis of subcutaneous large volumewearable injectors, subcutaneous autoinjectors, subcutaneous needle-freeinjectors and pre-filled syringes
§ Adiscussion on affiliated trends, key drivers and challenges, which are likelyto impact the industry's evolution, under a comprehensive SWOT framework
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow):
§ Phase of development
§ Approved
§ Pre-registration& Phase III
§ Phase II & PhaseII/III
§ Type of molecule
§ Cell and genetherapies
§ Monoclonal antibodies
§ Proteins
§ Peptides(recombinant)
§ Vaccines
§ Others
§ Target therapeuticarea
§ Autoimmune disorders
§ Blood disorders
§ Bone disorders
§ Genetic disorders
§ Metabolic disorders
§ Neurologicaldisorders
§ Oncological disorders
§ Respiratory disorders
§ Others
§ Type of drug deliverysystem
§ Large volume wearableinjectors
§ Autoinjectors
§ Prefilled syringes
§ Needle-free injectors
§ Drug reconstitutionsystems
§ Revenues fromlicensing deals
§ Upfront payments
§ Milestone payments
§ Key geographicalregions
§ North America
§ Europe
§ Asia Pacific
§ Rest of the World
§ Transcripts ofinterviews held with the following senior level representatives of stakeholdercompanies
§ Deborah Bitterfield(Founder and Chief Executive Officer, Lindy Biosciences)
§ Matthew Young(Founder and Chief Technology Officer, Oval MedicalTechnologies)
§ Steve Prestrelski(Founder and Chief Scientific Officer, XerisPharmaceuticals), Hong Qi (VicePresident, Product Development, XerisPharmaceuticals) and Scott Coleman(Senior Scientist, Formulation, XerisPharmaceuticals)
§ David Daily (Co-Founderand Chief Executive Officer, DALI Medical Devices)
§ Michael Reilly (Co-Founderand Chief Executive Officer and Co-Founder, Excelse Bio)
§ Poonam R Velagaleti(Co-Founder, i-novion)
§ Michael Hooven (ChiefExecutive Officer, Enable Injections)
§ Frederic Ors (ChiefExecutive Officer, Immunovaccine Technologies)
§ Patrick Anquetil(Chief Executive Officer, PortalInstruments)
§ Menachem Zucker (VicePresident and Chief Scientist, Elcam Medical)
§ Tiffany H. Burke(Director, Global Communications, WestPharmaceutical Services) and Graham Reynolds(Vice President and General Manager, Global Biologics, WestPharmaceutical Services)
§ David Heuzé(Communication Leader, MedinCell)
Keycompanies covered in the report
§ Adocia
§ Ajinomoto Bio-PharmaServices
§ Arecor
§ Alteogen
§ Ascendis Pharma
§ AvadelPharmaceuticals
§ Camurus
§ Creative BioMart
§ Creative Biolabs
§ DURECT
§ Eagle Pharmaceuticals
§ Halozyme Therapeutics
§ MedinCell
§ Xeris Pharmaceuticals
§ Serina Therapeutics
Foradditional details, please visit
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
1. Global AutoinjectorsMarket (3rd Edition), 2020-2030
2. Prefilled SyringesMarket (5th Edition), 2020-2030
3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and OtherMechanisms) Market, 2019-2030
4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030
AboutRoots Analysis
RootsAnalysis is one of the fastest growing market research companies, sharing freshand independent perspectives in the bio-pharmaceutical industry. The in-depthresearch, analysis and insights are driven by an experienced leadership teamwhich has gained many years of significant experience in this sector. If you’dlike help with your growing business needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
